Mesoblast (MESO) Other Non-Current Assets (2015 - 2025)
Mesoblast (MESO) posted quarterly Other Non-Current Assets of $1.2 million for Q4 2025, down 10.43% year-on-year from $1.3 million in Q4 2024, and down 7.87% on a QoQ basis from $1.3 million in Q2 2025.
Mesoblast (MESO) Other Non-Current Assets (2015 - 2025) Analysis & Trends
Mesoblast (MESO) has reported Other Non-Current Assets for 11 consecutive years, with $1.2 million the latest figure, recorded in Q4 2025.
- Quarterly Other Non-Current Assets fell 10.43% year-over-year to $1.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.2 million (down 10.43% YoY) and the FY2025 annual result came in at $1.3 million, down 38.34% from the prior year.
- Other Non-Current Assets declined to $1.2 million in Q4 2025 per MESO's latest filing, from $1.3 million in the prior quarter.
- Over the last five years, Other Non-Current Assets for MESO reached as high as $3.2 million in Q1 2021 and fell as low as $1.2 million in Q4 2025.
- A 5-year average of $2.0 million and a median of $2.0 million in 2021 frame the typical range for Other Non-Current Assets.
- Annual changes were most pronounced in 2021 — Other Non-Current Assets tumbled 47.93% — and 2023, when it rose 21.03%.
- Year by year, Other Non-Current Assets stood at $2.0 million in 2021, then retreated by 1.74% to $1.9 million in 2022, then climbed by 16.6% to $2.2 million in 2023, then slumped by 40.52% to $1.3 million in 2024, then declined by 10.43% to $1.2 million in 2025.
- According to Business Quant data, Other Non-Current Assets over the past three periods registered $1.2 million, $1.3 million, and $1.3 million for Q4 2025, Q2 2025, and Q4 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 1.02 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 104.24 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.26 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 2.13 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 289.41 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 124.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 14.48 Mn |
| 10 | Mesoblast | 2.08 Bn | 1.95 Bn | - | 1.19 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.19 Mn |
| Jun 30, 2025 | 1.30 Mn |
| Dec 31, 2024 | 1.33 Mn |
| Jun 30, 2024 | 2.10 Mn |
| Dec 31, 2023 | 2.24 Mn |
| Jun 30, 2023 | 2.33 Mn |
| Mar 31, 2023 | 2.39 Mn |
| Dec 31, 2022 | 1.92 Mn |
| Sep 30, 2022 | 1.90 Mn |
| Jun 30, 2022 | 1.93 Mn |
| Mar 31, 2022 | 1.97 Mn |
| Dec 31, 2021 | 1.96 Mn |
| Sep 30, 2021 | 1.95 Mn |
| Jun 30, 2021 | 1.72 Mn |
| Mar 31, 2021 | 3.20 Mn |
| Dec 31, 2020 | 3.21 Mn |
| Sep 30, 2020 | 3.33 Mn |
| Jun 30, 2020 | 3.31 Mn |
| Mar 31, 2020 | 3.24 Mn |
| Dec 31, 2019 | 3.32 Mn |